Expert Insights: Sourcing 3-Ethyl-4-methyl-3-pyrrolin-2-one for Pharmaceutical Applications
For scientists and formulators in the pharmaceutical research and development sector, the selection and sourcing of chemical building blocks are critical first steps in creating new therapeutic agents. 3-Ethyl-4-methyl-3-pyrrolin-2-one, identified by CAS number 766-36-9, stands out as a highly valuable intermediate, particularly in the synthesis of antidiabetic drugs like Glimepiride. Understanding its characteristics and where to procure it reliably is essential for the success of drug discovery and formulation.
Chemical Characteristics and Pharmaceutical Relevance
3-Ethyl-4-methyl-3-pyrrolin-2-one is a heterocyclic organic compound with the molecular formula C7H11NO. It typically presents as a white to straw-yellow crystalline solid. Its significance in pharmaceutical synthesis stems from its unique pyrrolinone structure, which allows for specific chemical transformations. A key requirement for its use as a pharmaceutical intermediate is high purity, typically specified at 99% minimum assay. This level of purity ensures that it can be effectively integrated into complex synthetic pathways, minimizing the risk of unwanted side reactions or the introduction of impurities into the final drug product.
Role in Glimepiride Synthesis and Beyond
The primary pharmaceutical application of 3-Ethyl-4-methyl-3-pyrrolin-2-one is its role as an intermediate in the synthesis of Glimepiride. Glimepiride is a widely used medication for managing type 2 diabetes. The compound serves as a foundational element that is chemically modified through a series of steps to construct the Glimepiride molecule. Its consistent availability and quality directly impact the efficiency and success rate of Glimepiride production. Beyond this specific application, the compound's reactive nature makes it a versatile building block for chemists exploring new synthetic routes and developing novel compounds in medicinal chemistry.
Finding a Reliable Source: What to Look For
When scientists and formulators need to buy 3-Ethyl-4-methyl-3-pyrrolin-2-one, it is crucial to partner with a reliable chemical supplier. Key factors to consider include:
- Purity and Specifications: Ensure the supplier provides a product that meets or exceeds the required purity standards, along with a detailed Certificate of Analysis (CoA).
- Manufacturer Expertise: Opt for suppliers who specialize in pharmaceutical intermediates and have a strong reputation for quality and consistency. Working with a direct manufacturer often provides better control over quality and pricing.
- Technical Data: Access to comprehensive technical data sheets (TDS) and safety data sheets (SDS) is vital for understanding product handling and application parameters.
- Sample Availability: The ability to procure samples for initial testing and formulation trials is essential for R&D purposes.
- Competitive Pricing: While quality is paramount, competitive pricing is also a consideration, especially for early-stage research or scale-up planning.
As a dedicated manufacturer and supplier of high-quality chemical intermediates from China, we understand the critical needs of the pharmaceutical R&D sector. We offer 3-Ethyl-4-methyl-3-pyrrolin-2-one (CAS 766-36-9) that meets rigorous quality standards, backed by competitive pricing and responsive customer support. We encourage scientists and formulators to reach out to us for their sourcing requirements, ensuring access to a vital building block for their pharmaceutical innovations.
Perspectives & Insights
Logic Thinker AI
“As a dedicated manufacturer and supplier of high-quality chemical intermediates from China, we understand the critical needs of the pharmaceutical R&D sector.”
Molecule Spark 2025
“We offer 3-Ethyl-4-methyl-3-pyrrolin-2-one (CAS 766-36-9) that meets rigorous quality standards, backed by competitive pricing and responsive customer support.”
Alpha Pioneer 01
“We encourage scientists and formulators to reach out to us for their sourcing requirements, ensuring access to a vital building block for their pharmaceutical innovations.”